Our Emerging Markets Equity team’s Michael Lai and Elizabeth Wu take a look at a new breed of innovative enterprises in China that could transform health care outcomes in the years ahead.

COVID-19 has cast a spotlight on health care systems around the world, with China in particular attracting attention due in part to its relative success in virus suppression and leading role in supplying medical products globally. In some instances, trends already in place are being reinforced. Structurally, we see increased innovation emerging in the health care sector, similar to the dynamism that characterized the early days of China’s technology boom. We believe several forces are at play:

  • The right place: China’s health care demand is swelling alongside an aging population, growing lifestyle diseases, and rising incomes. At the same time, increasingly open capital markets are channeling funds to health care companies with rising research and development (R&D) spending.
  • The right time: The government is pushing for innovation, efficiency, and self-sufficiency in health care to meet mounting medical needs. Various policies are lowering costs, while also addressing product quality and safety.
  • The right people: China is drawing overseas-educated Chinese scientists and entrepreneurs back to its shores. High-profile returnees, coupled with an abundant pool of homegrown talent, are propelling domestic drug and medical device development.

In our view, these forces have aligned to create a compelling long-term health care investment environment in China, while in the near term, the pandemic is accelerating the process of localization. Governments globally are seeking to reduce reliance on complex foreign supply chains for essential health care products, presenting both opportunities and challenges for Chinese companies.

Individuals in the United States can download the full article .pdf here to continue reading.

Individuals outside the United States can download the full article .pdf here to continue reading.